Improvement of ADHD symptoms in School Age Children and Adolescents with Autism via a Digital Smartglasses-based Socio-emotional Coaching Aid

Arshya Vahabzadeh\textsuperscript{1,3}, Neha U. Keshav\textsuperscript{1}, Joseph P. Salisbury\textsuperscript{1}, Ned T. Sahin\textsuperscript{1,2}\textsuperscript{*}

\textsuperscript{1}Brain Power, 1 Broadway 14\textsuperscript{th} Fl, Cambridge, MA, United States
\textsuperscript{2}Department of Psychology, Harvard University, Cambridge, MA, United States
\textsuperscript{3}Department of Psychiatry, Massachusetts General Hospital, Boston, MA, United States

\textsuperscript{*} Corresponding Author. Ned T. Sahin, PhD, Brain Power, 1 Broadway 14th Fl, Cambridge, MA 02142, USA. Email: sahin@post.harvard.edu.

**Abstract**

**Introduction**

People with autism spectrum disorder (ASD) commonly experience attention hyperactivity deficit disorder (ADHD) related symptoms, including hyperactivity, inattention, and impulsivity. One third of ASD cases may be complicated by the presence of ADHD. These dually diagnosed individuals face greater barriers to accessing treatment for ADHD, and respond less positively to primary pharmacological interventions. Non-pharmacological technology-aided tools for hyperactivity and inattention in people with ASD are being developed, although research into their efficacy and safety remains limited. This preliminary study describes the changes to ADHD-related symptoms in children and adolescents with ASD after use of the Empowered Brain system, a behavioral and social communication aid for ASD running on augmented reality smartglasses.

**Methods**

Eight children and adults with ASD (M:F ratio of 7:1, mean age 15 years, range 11.7-20.5 years) were recruited through a web-based research signup form. The baseline score on the hyperactivity subscale of the Aberrant Behavioral Checklist (ABC-H), a measure of hyperactivity, inattention, and impulsivity, determined their classification into a high ADHD-related symptom group ($n = 4$, ABC-H $\geq 13$) and a low ADHD-related symptom group ($n = 4$, ABC-H $< 13$). All participants received an intervention with Empowered Brain, where they used smartglasses-based social communication and behavioral modules while interacting with their caregiver. Caregiver-reported ABC-H scores were then calculated at 24- and 48-hours post-session.

**Results**

All eight participants were able to complete the intervention session. ABC-H scores were lower post-intervention for most participants at 24 hours ($n = 6$, 75%), and for all participants at 48 hours ($n = 8$, 100%). At 24-hours post-session, average ABC-H scores decreased by 54.4% in high ADHD symptom group and by 20% in the low ADHD symptom group. At 48-hours post-session ABC-H scores compared to baseline decreased by 56.4% in the high ADHD symptom group and by 66.3% in the low ADHD symptom group.

**Conclusion**

This study provides initial evidence for the efficacy of the Empowered Brain in reducing ADHD-related symptoms, such as hyperactivity, inattention, and impulsivity, in school-aged children and adolescents with ASD. There is potential to use this digital smartglasses intervention to target a broader array of mental health conditions that exhibit transdiagnostic attentional and social communication deficits, including schizophrenia and bipolar disorder. Further research is required to understand clinical importance of these observed changes, and to conduct longitudinal studies on this intervention with larger sample sizes.
Introduction

Autism Spectrum Disorder (ASD) is a lifelong developmental disorder characterized by challenges in social communication and the presence of repetitive behaviors and/or restricted interests. Many people with ASD experience symptoms of inattention and hyperactivity, and approximately one-third of people with ASD are diagnosable with attention deficit hyperactivity disorder (ADHD) (1, 2). There are considerable gaps in knowledge in how to provide optimal assessment and management of this group of patients (3). Early diagnosis and intervention are beneficial for both ASD (4) and ADHD (5). Evidence from genetic, cognitive, and behavioral research suggests that when ADHD and ASD co-occur, they may be considered a separate overarching condition (6-8), and a variety of ASD-ADHD developmental subtypes have already been proposed (9).

The combination of ASD and ADHD has been linked to both greater cognitive impairment (10, 11), general psychopathology (12, 13), emotional processing impairment (14), and significantly higher rates of some hyperactivity/impulsivity symptoms compared to individuals with ADHD alone (15). Furthermore, the co-occurrence of ADHD and ASD is associated with a greater risk of developing other psychiatric disorders such as schizophrenia, bipolar disorder, and anxiety disorder, compared to controls and individuals with either condition alone (16). The pervasive nature of impairments in social communication and attention across psychiatric disorders may suggest that these deficits should be investigated transdiagnostically, an approach advocated by the NIMH Research domain criteria RDoC framework (17). Attentional and social communication deficits have been identified in many disorders of brain function including schizophrenia (18, 19), bipolar disorder (20, 21), anxiety disorders (22), and traumatic brain injury (23, 24). Therefore, the study of individuals with combined ASD and ADHD can help elucidate the basis of a wide variety of disorders of the brain.

It is important to address ADHD, and while the leading approach has been psychopharmacological medication, people with co-occurring ASD and ADHD have been found to be less likely to receive appropriate treatment for their ADHD (15), and appear to respond less favorably to treatment when compared to individuals with ADHD alone (25). Additional concerns about ADHD treatment, in particular stimulant medication, focus on their long-term effectiveness (26), side effects (27), and parental reservation about their use (28). Yet, evidence also shows that leaving individuals with untreated ADHD may lead to considerable negative social and behavioral sequelae, including greater risk of academic failure (29), alcohol and drug use (30), and contact with the criminal justice system.

Little research has described the impact of digital interventions on people with ASD who demonstrate ADHD symptoms (37). There has been some preliminary research to show the utility of augmented reality interventions in ASD samples (38-40). Intervention based on augmented reality has also been shown to help improve ADHD symptoms in people with ASD, with improvements in both selective and sustained attention in children with ASD (38). We have previously described the delivery of social communication coaching on augmented reality smartglasses via Empowered Brain (previously the Brain Power Autism System; (41). Our early pilot report on two boys with ASD demonstrated short-term improvements in the hyperactivity subscale of the Aberrant Behavioral Checklist (ABC-H) (41), a validated instrument that assesses hyperactivity, impulsivity, attention, and non-compliance (42). The ABC-H has previously been used as a key outcome measure in ADHD treatment studies in children with ASD (43-47).

In this study, we explore the short-term effect of an Empowered Brain intervention on ADHD symptoms in a group of 8 children and adults with ASD. We document caregiver-reported ADHD symptoms as measured by the ABC-H and discuss the implications of these results on future research in the field.
The Empowered Brain system

Empowered Brain is a combination of modern smartglasses and educational modules targeting socio-emotional and behavioral management skills (41, 48). Smartglasses are lightweight head-worn computers with a small transparent display that can provide guidance to users through both visual and audio cues (Figure 1). Empowered Brain can collect a wide variety of user data through an in-built sensor array that includes camera, microphone, touchpad, a “blink” sensor, gyroscope, and accelerometer. Empowered Brain includes modules that utilize these sensors to deliver social communication and cognitive skills coaching. This digital approach may be particularly valuable to both people with ASD (49) and people with ADHD (50, 51).

Figure 1. Google Glass, prototypical head-worn smartglasses with in-built sensors, as well as a small screen and a bone conduction speaker to provide a private audio-visual experience. Empowered Brain integrates Google Glass with a range of assistive and educational modules. Modules were developed through an iterative, user-centered design and evaluation process in conjunction with behavioral specialists and families with autistic children.

For example, Empowered Brain incorporates the Face2Face module, software that helps guide users to pay attention to socially salient visual stimuli (human faces; Figure 2 and Figure 3). The ability to pay attention to important social stimuli, and to direct gaze towards the most socially salient features of the face, have been identified as a key challenge in ASD (52). When the Face2Face module is running, Empowered Brain is able to identify the presence of human faces within its visual field, and helps direct users towards the human faces through engaging visual cartoon-like images and guidance arrows. As the user pays more visual attention to the human face, they earn points and other in-game rewards. The points stop accumulating after a short period of time to avoid coaching users to stare.

Figure 2. Demonstration of the use of the Empowered Brain System. (A) Child and partner sitting opposite one another with child wearing smartglasses. (B) Close-up view of the child wearing the smartglasses. The child can see the in-game view, displayed on the left side of the insert, through the optical display of the computerized smartglasses. [Copyright Brain Power]

Using a similar approach, Empowered Brain can not only detect human faces, but also human facial emotions when running the Emotion Charades module (Figure 4). In Emotion Charades, users have
a game-like experience in which they identify the emotions of another person. Empowered Brain rewards correct answers with in-game rewards or provides guidance when needed.

![Empowered Brain's Face2Face module.](image)

**Figure 3. Empowered Brain’s Face2Face module.** (A) Face2Face is a two-player game that encourages face-directed gaze during social interactions. (B) Child’s view on smartglasses: Face2Face detects the face in the field of view. (C) As the child maintains gaze towards the partner’s face, the ‘progress circle’ fills up and the child continues to earn points (upper left). (D) When the progress circle is full, the child earns a star (lower left) and a mask is displayed as a reward. [Copyright Brain Power]

Additionally, the system incorporates mechanisms to alter the difficulty associated with using each gamified app. One method is to alter the attentional challenge by displaying virtual elements that will either help to enhance attention, or to act as distractors to the social stimuli that the user is tasked to interact with. These virtual elements are overlaid over the user’s real-world view and include both dynamic real-time positional cues based on user movement and physiology, as well as reward-based virtual elements that provide feedback on the user’s in-app performance.

A series of research studies have investigated the use of Empowered Brain in ASD samples. The feasibility of using Empowered Brain in ASD was established during testing with two boys with ASD, both of whom demonstrated improvements in ASD symptoms as measured by the ABC (41). Empowered Brain was safely used with no reported serious negative effects in 18 children and adults with ASD (53). A separate report of 21 users with ASD found Empowered Brain was well tolerated, with 91% of participants demonstrating tolerability across three separate measures (48). The same study also found that 94% of participants reported the use of Empowered Brain to be comfortable. Additionally, the form factor of the computerized smartglasses of Empowered Brain have been described as desirable for school use by children with ASD (54). Exploratory studies into the longitudinal use of Empowered Brain in school settings as a facilitative social-emotional learning tool has been reported by multiple educators as having a positive impact on student learning and social communication (55). Empowered Brain has also been found to improve social communication as measured by longitudinal educator and parental scores on the SRS-2, a gold standard validated measure of social communication functioning in ASD (56).

The facial affective analytics component of Empowered Brain was developed in partnership with Affectiva, an emotion artificial intelligence company. The Empowered Brain also utilizes experimental artificial intelligence technologies developed by
Methods

IRB Approval

The methods and procedures of this study were approved by Acentral, Inc., Institutional Review Board, an affiliate of the Commonwealth of Massachusetts Department of Public Health.

Participants

Eight children and adults with ASD signed up to take part in this research through a web-based research interest form (average age: 15 years, range 11.7 – 20.5; 7 males, 1 female). Participant demographics are summarized in Tables 1 and 2. Written consent was obtained from the legal guardians of children and from cognitively-abled adults. Participants between 7 and 17 years-old provided written assent, when they were able to.

All caregivers of participants were questioned whether they had a past history of ADHD, and whether they were currently receiving treatment for ADHD. Additionally all participants had a baseline ABC-H and Social Communication Questionnaire (SCQ) (57).

Method

The ABC-H is a subscale of the ABC, and measures key ADHD symptoms such as inattention, impulsivity, and hyperactivity. The ABC has been extensively used in the developmentally disabled population, and the ABC-H has been used as an outcome measure of studies that have investigated the treatment of ADHD in populations with concurrent
ASD (43-47). In the assessment of ADHD symptoms in ASD, the ABC has shown itself to have superior psychometric properties, in particular validity (58) and reliability (59), compared to other rating scales of ADHD symptoms in children with developmental disorders (such as ASD). The ABC-H includes items that rate key ADHD symptoms. Specifically, the ABC-H assesses inattention/impulsivity through items that require the rater to assess whether client is “easily distractible”, “does not pay attention to instructions”, “pays no attention when spoken to”, or is “impulsive”.

Following these baseline assessments, the participants were stratified into high and low ADHD symptom groups based on their baseline ABC-H score. The cut-off scores for the high ADHD group is 13 for male participants, and 8 for the single female participant. These scores were determined by prior research that recorded the ABC scores for a sample of 666 people with developmental disorders, and found a mean ABC-H score of 13.38 for males and 8.12 for females (60). Accordingly, males with a score of 13 or higher and females with a score of 8 or higher were considered to have high ADHD symptoms (mean high ABC-H group score = 25.75), while those with a lower score were deemed as having low ADHD symptoms (mean low ABC-H group score = 5.5). Half of the participants had a history of ADHD (n = 4, 50%), three of whom were receiving active treatment at the time of testing. Of note, based on their ABC-H scores as above, two participants that were previously diagnosed with ADHD were categorized in the low ADHD symptom group, while the remaining two were categorized into the high ADHD symptom group. Despite the past history of ADHD diagnosis, the ABC-H was used as a stratification method as it provided a numerical measure of recent (baseline) ADHD symptom burden. This numerical subscale allows for a more quantitative measure of change in rated items. While a clinical history of ADHD was obtained for the participants, the clinical diagnosis of ADHD in ASD is challenging (61), and it was only with the release of the DSM-5 (62) that it became possible to diagnose ADHD in an individual with ASD. Prior to the release of the DSM-5, the DSM-IV TR specifically excluded a diagnosis of ADHD being made when an individual had a diagnosis of ASD. Therefore, while background information regarding ADHD history is important, the ABC-H was felt to be a more accurate measure of ADHD symptom load to determine the stratification into low and high ADHD symptom groups.

All participants had a baseline SCQ (57) as a validated measure of their ASD symptoms. The SCQ score demonstrated that participants represented a wide range of social communication abilities, from 11 to 28 points (mean score 18).

**Procedure for Testing**

All participants were accompanied by a caregiver to the testing session. The participants and their caregivers were oriented to Empowered Brain and Google Glass, and their ability to tolerate wearing the smartglasses was measured. Once the participants showed they were able to wear the smartglasses for at least one minute, the participants were able to use Empowered Brain social communication modules and had a series of gamified experiences while interacting with their caregiver, including using Empowered Brain modules such as Face2Face and Emotion Charades (Fig. 2, 3). Empowered Brain modules help users to recognize and direct their attention towards socially salient stimuli such as human faces (in particular, the central part of the face, including eye regions), emotional facial expressions, and changes in social environment. Participants and caregivers were able to verbalize any concerns or difficulties in using Empowered Brain both during and immediately after the session. An ABC-H score was obtained at 24-hours and at 48-hours post session through the caregiver’s report. A clinically significant change in ABC-H was determined by a 25% or more change in the score, a standard that has previously been utilized in combination with another scale to determine responders to ADHD treatment in an ASD population (43).
Table 1: Individual Participant Demographics

| Participant Identifier | Age (years) | Gender | SCQ | ADHD Diagnosis? | ADHD Treatment |
|------------------------|-------------|-------|-----|-----------------|----------------|
| 1                      | 12.6        | M     | 22  | No              | No             |
| 2                      | 11.7        | M     | 11  | Yes             | Yes            |
| 3                      | 12.4        | M     | 23  | No              | No             |
| 4                      | 13.4        | F     | 18  | Yes             | Yes            |
| 5                      | 16.9        | M     | 16  | Yes             | No             |
| 6                      | 20.5        | M     | 28  | No              | No             |
| 7                      | 19.4        | M     | 15  | Yes             | Yes            |
| 8                      | 13.4        | M     | 12  | No              | No             |

Table 2: Overall Participant Demographics

|                                | 8          |
|--------------------------------|------------|
| Number of users                | 8          |
| Age (mean ± SD)                | 15 ± 3.4   |
| Range = 11.7 – 20.5 years      |            |
| Participant gender             | Male: 7 (87.5%) |
|                                | Female: 1 (12.5%) |
| Prior ADHD diagnosis           | Yes: 4 (50%) |
|                                | No: 4 (50%) |
| ADHD treatment during study    | Yes: 3     |
|                                | No: 5      |
| Social Communication Questionnaire (SCQ) Score (mean ± SD) | 18.1 ± 5.8 | Range: 11 – 28 |

Exclusions

Individuals who had expressed interest via the website signup but who had a known history of epilepsy or seizure disorder were not enrolled in this study. Users who had any uncontrolled or severe medical or mental health condition that would make participation in the study predictably hazardous were also not eligible for enrollment. Information regarding potential exclusions to this study was obtained directly from the caregivers of the participants.

Results

All participants were able to use smartglasses and complete the coaching session. The high ADHD-related symptom group had a similar ASD severity to the low ADHD-related symptom group (18.5 vs 17.6 SCQ score), but consistent of younger participants (12.5 vs 17.6 years). ABC-H scores were lower post-intervention for most participants at 24 hours \( n = 6, \ 75\% \), and for all participants at 48 hours \( n = 8,\ 100\% \). At 24-hours post-session, average ABC-H scores decreased by 54.4% in the high ADHD symptom group and by 20% in the low ADHD symptom group. At 48-hours post-session ABC-H scores compared to baseline decreased by 56.4% in the high ADHD symptom group and by 66.3% in the low ADHD symptom group.

The high ADHD-related symptom group consisted of four participants who demonstrated an average ABC-H score of 25.75 at the start of the study (Table 3). The high ADHD-related symptom group reported a reduction in average ABC-H score at 24-hours (ABC-H score: -12, -54.9% reduction from baseline) and at 48-hours post-session (-11.75, -56.4%). The low ADHD-related symptom group consisted of four participants who had an average ABC-H score of 5.5 at the start of the study (Table 4). The low ADHD-related symptom group had decreased average ABC-H score at 24-hours (-1, -20%) and 48-hours post-session (-3.5, 66.3%). The average reduction in ABC-H score for the high ADHD-related symptom group was greater than the low ADHD-related symptom group at both 24-hours (12 vs 1 point) and 48-hours (11.75 vs 3.5 points) post-session. The ABC-H scores
of the participants are presented graphically in Figure 2.

It is noted that while the participants in the high ADHD-related symptoms group were younger, they had a similar ASD symptom severity as measured by the SCQ to the low ADHD-related symptom group. It is perhaps not a surprise to find that the high symptom group was younger given that the ABC-H subscale is weighted towards hyperactivity, and hyperactivity is an ADHD-symptom that improves with age (63).

### Table 3: High ADHD-related Symptom Groups and ABC-H Scores

| Participant Identifier | ABC-H Score & Percentage Change Relative to Baseline |
|------------------------|-----------------------------------------------------|
|                        | Baseline Score | 24-Hour Score | 24-Hour % Change | 48-Hour Score | 48-Hour % Change |
| 1                      | 17             | 1             | -94.1            | 1             | -94.1            |
| 2                      | 48             | 40            | -16.7            | 42            | -12.5            |
| 3                      | 24             | 3             | -83.3            | 4             | -792             |
| 4                      | 14             | 11            | -21.4%           | 9             | -35.7%           |
| **Average**            | 25.75          | 13.75         | -54.9            | 14            | -56.4            |

### Table 4: Low ADHD-related Symptom Groups and ABC-H Scores

| Participant Identifier | ABC-H Score & Percentage Change Relative to Baseline |
|------------------------|-----------------------------------------------------|
|                        | Baseline Score | 24-Hour Score | 24-Hour % Change | 48-Hour Score | 48-Hour % Change |
| 5                      | 4              | 6             | +50              | 1             | -75              |
| 6                      | 5              | 5             | 0                | 4             | -20              |
| 7                      | 10             | 7             | -30              | 3             | -70              |
| 8                      | 3              | 0             | -100             | 0             | -100             |
| **Average**            | 5.5            | 4.5           | -20              | 2             | -66.3            |
**Discussion**

While many people with ASD struggle with symptoms of ADHD, including hyperactivity, impulsivity, and inattention, considerable gaps in knowledge remain in regard to their optimum assessment and management (3). The combination of ADHD and ASD has not only been linked to greater impairment (10, 11) and psychopathology (12, 13), but also reduced access and response to psychopharmacological treatment for ADHD (15) (25). These are important considerations given the substantial negative sequelae of untreated ADHD (29, 30). There has been increasing interest in developing digital interventions to address the symptoms of ASD or ADHD, but few technological interventions have been studied for people with ASD and ADHD symptoms. This population may potentially benefit from such approaches.

All participants managed to complete the Empowered Brain intervention session without any reported negative effects, and all participants tolerated using smartglasses for the duration of the testing session. This is important as a major limiting factor in the use and continued engagement of assistive technologies is their usability, tolerability, and associated negative effects.

Most participants demonstrated improvements in ADHD-related symptoms following the intervention at both 24 hours ($n = 6, \text{75\%}$), and 48 hours ($n = 8, \text{100\%}$) post-session. One participant in the high symptom group was noted to have had a greater reduction at 24 hours than 48 hours, while a participant in the low symptom group was noted to have had an increase in ADHD-related symptoms at 24 hours followed by a large decrease from baseline at 48 hours.

When group mean ABC-H changes are calculated, the high ADHD-related symptom group demonstrated a significant response (greater than 25% improvement in ABC-H score) at both 24- and 48-hours (-54.9\% and -56.4\%, respectively). The low ADHD-related symptom group appears to have demonstrated a response at 48-hours (-66.3\%), but not at 24-hours (-20\%). The authors, who include subspecialist clinicians, advise caution in assessing the low ADHD-related symptom group, given the low baseline and small absolute score changes. Such results may render the findings in this group as not

![ABC-H Score Change by Participant Identifier](image)

Figure 2: ABC-H score change by participant identifier from base to 48 hours post-intervention.
being as clinically significant as the outcomes associated with the high ADHD-related symptom group. Future larger studies would allow for more robust statistical analysis and conclusions to be made.

There are several important limitations to this work that deserve mention. Firstly, the number of children and adults in this report was relatively small ($n = 8$), although a sizeable sample relative to other research on novel technologies in ASD, especially in regard to other smartglasses research (41, 48). While quantitative approaches using validated scales are very useful, future research efforts would also benefit from the use of qualitative approaches, and some early results of such methods have been reported (55).

We should certainly consider the potential for a expectancy effect (64) in using this technology, especially given that the testing session was a novel experience for both the participant and the caregiver. However, the potential for this effect should also be tempered by our knowledge that transitions or new experiences have been associated with extreme distress in people with ASD, so much so that it is a characteristic part of diagnosis (62). We noted that none of the participants encountered any noticeable distress or problems with using the smartglasses.

It would be useful for future research to incorporate a larger sample size, with more female participants. One can also see the benefit of age-matched neurotypical and ADHD-only controls. While the ABC-H is a very useful scale to use in this context, the use of broader ADHD-related measures would also provide for further insights. Despite our findings, the broader generalizability of our results to the wider ASD population will remain limited until further research is undertaken.

This report can hopefully pave the way for more funding and interest to study the potential application of this emerging technology to not just dually diagnosed ADHD and ASD samples, but more broadly to other categorical psychiatric diagnoses that also exhibit both attentional and social communication impairments. Such diagnoses include schizophrenia, bipolar disorder, and anxiety disorder. While deficits in social communication occur across many psychiatric disorders, the major of digital social communication interventions have been studied in ASD alone (65). Therefore, research and development of an intervention that can target transdiagnostic symptoms could be valuable in both clinical scenarios, and in research utilizing the RDoC framework.

Smartglasses may have a particularly unique role in this respect, as they also contain a variety of quantitative sensors that are more closely located to the main perceptual apparatus of the brain than any other wearable technology. These sensors can collect and help analyze sensor data to help classify human behavior. This digital phenotyping approach aims to detect changes in affective and behavioral states associated with both improvements and deteriorations in psychiatric disorders, and help to identify new methods to subtype disorders (66).

**Conclusion**

Empowered Brain is a smartglasses-based social communication intervention that has been previously shown to improve social communication functioning in ASD. This report provides early evidence for the efficacy of Empowered Brain to reduce ADHD symptoms, such as hyperactivity, inattention, and impulsivity, in school-aged children and adolescents with ASD. Our results also suggest that, despite concerns about increased distraction and reduced attentiveness, the intervention did not result in any increased ADHD symptoms in any of the participants at 48 hours post-intervention.

Empowered Brain is being developed as a tool that can be used by caregivers, therapists, and educators to deliver socio-emotional interventions to users with ASD. It is designed as a tool that can be used on a daily basis for 10-20 minutes per intervention. While this study reports on the impact of Empowered Brain on ADHD symptoms after a single intervention, further research is required to understand how the longitudinal use of this technology may impact ADHD symptoms in people with ASD. This technology also has potential to address the attentional and social communication deficits that are transdiagnostically present across psychiatric disorders. Data collection via sensors that are proximally situated to the principal human perceptual organs may result in a more ecologically valid digital phenotyping approach. This digital phenotyping approach may aid the research of proposed developmental subtypes of a distinct ASD-ADHD...
combination disorder, and more broadly, psychiatric
and brain injury-related disorders.

REFERENCES

1. Leyfer OT, Folstein SE, Bacalman S, Davis NO, Dinh E, Morgan J, et al. Comorbid psychiatric disorders in children with autism: interview development and rates of disorders. J Autism Dev Disord. 2006;36(7):849-61.
2. Rosenberg RE, Kaufmann WE, Law JK, Law PA. Parent report of community psychiatric comorbid diagnoses in autism spectrum disorders. Autism Res Treat. 2011;2011:405849.
3. May T, Brignell A, Hawi Z, Brereton A, Tonge B, Bellgrove M, et al. Trends in the Overlap of Autism Spectrum Disorder and Attention Deficit Hyperactivity Disorder: Prevalence, Clinical Management, Language and Genetics. Current Developmental Disorders Reports. 2018:1-9.
4. Estes A, Munson J, Rogers SJ, Greenson J, Winter J, Dawson G. Long-term outcomes of early intervention in 6-year-old children with autism spectrum disorder. Journal of the American Academy of Child & Adolescent Psychiatry. 2015;54(7):580-7.
5. DuPaul GJ, Kern L, Caskie GI, Volpe RJ. Early intervention for young children with attention deficit hyperactivity disorder: Prediction of academic and behavioral outcomes. School Psychology Review. 2015;44(1):3-20.
6. Ronald A, Simonoff E, Kuntsi J, Asherson P, Plomin R. Evidence for overlapping genetic influences on autistic and ADHD behaviours in a community twin sample. J Child Psychol Psychiatry. 2008;49(5):535-42.
7. van der Meer JM, Oerlemans AM, van Steijn DJ, Lappenschaar MG, de Sonneville LM, Buitelaar JK, et al. Are autism spectrum disorder and attention-deficit/hyperactivity disorder different manifestations of one overarching disorder? Cognitive and symptom evidence from a clinical and population-based sample. J Am Acad Child Adolesc Psychiatry. 2012;51(11):1160-72 e3.
8. Ames CS, White SJ. Are ADHD traits dissociable from the autistic profile? Links between cognition and behaviour. J Autism Dev Disord. 2011;41(3):357-63.
9. Rommelse N, Buitelaar JK, Hartman CA. Structural brain imaging correlates of ASD and ADHD across the lifespan: a hypothesis-generating review on developmental ASD–ADHD subtypes. Journal of Neural Transmission. 2017;124(2):259-71.
10. Sinzig J, Walter D, Doepfner M. Attention deficit/hyperactivity disorder in children and adolescents with autism spectrum disorder: symptom or syndrome? J Atten Disord. 2009;13(2):117-26.
11. Yerys BE, Wallace GL, Sokoloff JL, Shook DA, James JD, Kenworthy L. Attention deficit/hyperactivity disorder symptoms moderate cognition and behavior in children with autism spectrum disorders. Autism Res. 2009;2(6):322-33.
12. Holtmann M, Bolte S, Poustka F. Attention deficit hyperactivity disorder symptoms in pervasive developmental disorders: association with autistic behavior domains and coexisting psychopathology. Psychopathology. 2007;40(3):172-7.
13. Jang J, Matson JL, Williams LW, Tureck K, Goldin RL, Cervantes PE. Rates of comorbid symptoms in children with ASD, ADHD, and comorbid ASD and ADHD. Res Dev Disabil. 2013;34(8):2369-78.
14. Tye C, Battaglia M, Bertoletti E, Ashwood KL, Azadi B, Asherson P, et al. Altered neurophysiological responses to emotional faces discriminate children with ASD, ADHD and ASD+ ADHD. Biological psychology. 2014;103:125-34.
15. Joshi G, Faraone SV, Wozniak J, Tarko L, Fried R, Galdo M, et al. Symptom Profile of ADHD in Youth With High-Functioning Autism Spectrum Disorder: A Comparative Study in Psychiatrically Referred Populations. J Atten Disord. 2017;21(10):846-55.
16. Chen M-H, Wei H-T, Chen L-C, Su T-P, Bai Y-M, Hsu J-W, et al. Autistic spectrum disorder, attention deficit hyperactivity disorder, and psychiatric comorbidities: A nationwide study. Research in Autism Spectrum Disorders. 2015;10:1-6.
17. Insel T, Cuthbert B, Garvey M, Heinssen R, Pine DS, Quinn K, et al. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am Psychiatric Assoc; 2010.
18. Morrison KE, Pinkham AE, Penn DL, Kelsven S, Ludwig K, Sasson NJ. Distinct profiles of social skill
in adults with autism spectrum disorder and schizophrenia. Autism Research. 2017;10(5):878-87.

19. Gold JM, Robinson B, Leonard CJ, Hahn B, Chen S, McMahon RP, et al. Selective Attention, Working Memory, and Executive Function as Potential Independent Sources of Cognitive Dysfunction in Schizophrenia. Schizophrenia bulletin. 2017.

20. Pagliaccio D, Wiggins JL, Adleman NE, Harkins E, Curhan A, Towbin KE, et al. Behavioral and neural sustained attention deficits in bipolar disorder and familial risk of bipolar disorder. Biological psychiatry. 2017;82(9):669-78.

21. McClure EB, Treland JE, Snow J, Schmajuk M, Dickstein DP, Towbin KE, et al. Deficits in social cognition and response flexibility in pediatric bipolar disorder. American Journal of Psychiatry. 2005;162(9):1644-51.

22. Halls G, Cooper PJ, Creswell C. Social communication deficits: specific associations with social anxiety disorder. Journal of affective disorders. 2015;172:38-42.

23. Beaulieu-Bonneau S, Fortier-Brochu E, Ivers H, Morin CM. Attention following traumatic brain injury: neuropsychological and driving simulator data, and association with sleep, sleepiness, and fatigue. Neuropsychological rehabilitation. 2017;27(2):216-38.

24. Steel J, Ferguson A, Spencer E, Togher L. Social communication assessment during post-traumatic amnesia and the post-acute period after traumatic brain injury. Brain injury. 2017;31(10):1320-30.

25. Research Units on Pediatric Psychopharmacology Autism N. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry. 2005;62(11):1266-74.

26. van de Loo-Neus GH, Rommelse N, Buitelaar JK. To stop or not to stop? How long should medication treatment of attention-deficit hyperactivity disorder be extended? Eur Neuropsychopharmacol. 2011;21(8):584-99.

27. Graham J, Baneaenschewski T, Buitelaar J, Coghill D, Danckaerts M, Dittmann RW, et al. European guidelines on managing adverse effects of medication for ADHD. Eur Child Adolesc Psychiatry. 2011;20(1):17-37.

28. Berger I, Dor T, Nevo Y, Goldzweig G. Attitudes toward attention-deficit hyperactivity disorder (ADHD) treatment: parents’ and children’s perspectives. J Child Neurol. 2008;23(9):1036-42.

29. Daley D, Birchwood J. ADHD and academic performance: why does ADHD impact on academic performance and what can be done to support ADHD children in the classroom? Child Care Health Dev. 2010;36(4):455-64.

30. Hammerness P, Petty C, Faraone SV, Biederman J. Do Stimulants reduce the risk for alcohol and substance use in youth with ADHD? A secondary analysis of a prospective, 24-Month Open-Label Study of Osmotic-Release Methylphenidate. Journal of attention disorders. 2017;21(1):71-7.

31. Mishra J, Sagar R, Joseph AA, Gazzaley A, Merzenich MM. Training sensory signal-to-noise resolution in children with ADHD in a global mental health setting. Transl Psychiatry. 2016;6:e781.

32. Blandón DZ, Muñoz JE, Lopez DS, Gallo OH, editors. Influence of a BCI neurofeedback videogame in children with ADHD. Quantifying the brain activity through an EEG signal processing dedicated toolbox. Computing Conference (CCC), 2016 IEEE 11th Colombian; 2016: IEEE.

33. Cortese S, Ferrin M, Brandeis D, Holtmann M, Aggensteiner P, Daley D, et al. Neurofeedback for Attention-Deficit/Hyperactivity Disorder: Meta-Analysis of Clinical and Neuropsychological Outcomes From Randomized Controlled Trials. J Am Acad Child Adolesc Psychiatry. 2016;55(6):444-55.

34. McCoy BR. Digital distractions in the classroom phase II: Student classroom use of digital devices for non-class related purposes. 2016.

35. Lowe T. Utilizing Cell Phones as a Learning Tool in the Classroom: Preventing Distractions while Increasing Student Engagement 2017.

36. Thomas K, Muñoz MA. Hold the phone! High school students’ perceptions of mobile phone integration in the classroom. American Secondary Education. 2016;44(3):19.

37. Sonuga-Barke EJ, Brandeis D, Cortese S, Daley D, Ferrin M, Holtmann M, et al. Nonpharmacological interventions for ADHD: systematic review and meta-analyses of randomized controlled trials of dietary and psychological treatments. Am J Psychiatry. 2013;170(3):275-89.
38. Escobedo L, Tentori M, Quintana E, Favela J, Garcia-Rosas D. Using augmented reality to help children with autism stay focused. Pervasive Computing, IEEE. 2014;13(1):38-46.
39. da Silva CA, Fernandes AR, Grohmann AP. STAR: Speech Therapy with Augmented Reality for Children with Autism Spectrum Disorders. Enterprise Information Systems: Springer; 2014. p. 379-96.
40. Escobedo L, Nguyen DH, Boyd L, Hirano S, Rangel A, Garcia-Rosas D, et al., editors. MOSOCO: a mobile assistive tool to support children with autism practicing social skills in real-life situations. Proceedings of the SIGCHI Conference on Human Factors in Computing Systems; 2012: ACM.
41. Liu R, Salisbury JP, Vahabzadeh A, Sahin NT. Feasibility of an Autism-Focused Augmented Reality Smartglasses System for Social Communication and Behavioral Coaching. Frontiers in Pediatrics. 2017;5(145).
42. Aman MG, Singh NN, Stewart AW, Field CJ. The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic. 1985;89(5):485-91.
43. Arnold LE, Aman MG, Cook AM, Witwer AN, Hall KL, Thompson S, et al. Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial. J Am Acad Child Adolesc Psychiatry. 2006;45(10):1196-205.
44. Bent S, Hendren RL, Zandi T, Law K, Choi JE, Widjaja F, et al. Internet-based, randomized, controlled trial of omega-3 fatty acids for hyperactivity in autism. J Am Acad Child Adolesc Psychiatry. 2014;53(6):658-66.
45. Troost PW, Steenhuis M-P, Tuynman-Qua HG, KaVerdijk LJ, Buitelaar JK, Minderaa RB, et al. Atomoxetine for Attention-Deficit/Hyperactivity Disorder Symptoms in Children with Pervasive Developmental Disorders: A Pilot Study. Journal of Child & Adolescent Psychopharmacology. 2006;16(5):611-9.
46. Posey DJ, Wiegand RE, Wilkerson J, Maynard M, Stigler KA, McDougle CJ. Open-label atomoxetine for attention-deficit/hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders. Journal of Child & Adolescent Psychopharmacology. 2006;16(5):599-610.
47. Charansil C. Efficacy of atomoxetine in children with severe autistic disorders and symptoms of ADHD: an open-label study. Journal of attention disorders. 2011;15(8):684-9.
48. Keshav NU, Salisbury JP, Vahabzadeh A, Sahin NT. Social Communication Coaching Smartglasses: Well Tolerated in a Diverse Sample of Children and Adults With Autism. JMIR mHealth and uHealth. 2017;5(9):e140.
49. Whyte EM, Smyth JM, Szerf KS. Designing Serious Game Interventions for Individuals with Autism. J Autism Dev Disord. 2015;45(12):3820-31.
50. Doxi S, Van der Oord S, Wiers RW, Prins PJ. Can motivation normalize working memory and task persistence in children with attention-deficit/hyperactivity disorder? The effects of money and computer-gaming. J Abnorm Child Psychol. 2012;40(5):669-81.
51. Prins PJ, Doxi S, Ponsieno A, ten Brink E, van der Oord S. Does computerized working memory training with game elements enhance motivation and training efficacy in children with ADHD? Cyberpsychol Behav Soc Netw. 2011;14(3):115-22.
52. Klin A, Jones W, Schultz R, Volkmar F, Cohen D. Visual fixation patterns during viewing of naturalistic social situations as predictors of social competence in individuals with autism. Archives of general psychiatry. 2002;59(9):809-16.
53. Sahin NT, Keshav NU, Salisbury JP, Vahabzadeh A. An Augmented Reality Social Communication Aid for Children and Adults with Autism: User and caregiver report of safety and lack of negative effects. bioRxiv. 2017.
54. Sahin NT, Keshav NU, Salisbury JP, Vahabzadeh A. Second version of Google Glass as a wearable socio-affective aid in children with autism: Theoretical basis, Usability, and desirability in schools. JMIR Human Factors (in press). 2017.
55. Keshav NU, Abdus-Sabur R, Liu R, Huey K, Salisbury JP, et al. Longitudinal Socio-Emotional Learning Intervention for Autism Via Smartglasses: Qualitative School Teacher Report of Practicality and Efficacy in General and Special Education Classroom Settings. 2018.
56. Sahin NT, Abdus-Sabur R, Keshav NU, Liu R, Salisbury JP, Vahabzadeh A. Augmented Reality Intervention for Social Communication in Autism in a School Classroom: Rated by Teachers and Parents as
Effective and Usable in a Controlled, Longitudinal Pilot Study. Psyarxiv. 2018.

57. Rutter M, Bailey A, Lord C. The social communication questionnaire: Manual: Western Psychological Services; 2003.

58. Miller ML, Fee VE, Jones CJ. Psychometric properties of ADHD rating scales among children with mental retardation. Res Dev Disabil. 2004;25(5):477-92.

59. Miller ML, Fee VE, Netterville AK. Psychometric properties of ADHD rating scales among children with mental retardation I: reliability. Res Dev Disabil. 2004;25(5):459-76.

60. Marshburn EC, Aman MG. Factor validity and norms for the Aberrant Behavior Checklist in a community sample of children with mental retardation. Journal of autism and developmental disorders. 1992;22(3):357-73.

61. Stevens T, Peng L, Barnard-Brak L. The comorbidity of ADHD in children diagnosed with autism spectrum disorder. Research in Autism Spectrum Disorders. 2016;31:11-8.

62. Association AP. Diagnostic and Statistical Manual of Mental Disorders (DSM-5®): American Psychiatric Pub; 2013.

63. Kooij SJ, Bejerot S, Blackwell A, Caci H, Casas-Brugué M, Carpentier PJ, et al. European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD. BMC psychiatry. 2010;10(1):67.

64. Kirsch I. Response expectancy as a determinant of experience and behavior. American Psychologist. 1985;40(11):1189.

65. Wieckowski AT, White SW. Application of technology to social communication impairment in childhood and adolescence. Neuroscience & Biobehavioral Reviews. 2017;74:98-114.

66. Onnela JP, Rauch SL. Harnessing Smartphone-Based Digital Phenotyping to Enhance Behavioral and Mental Health. Neuropsychopharmacology. 2016;41(7):1691-6.